Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multimodality therapy for Pancoast tumor.

Samir Narayan1, Charles R Thomas

  • 1Department of Radiation Oncology, University of California Davis Health System, 4501 X Street, Sacramento, CA 95817, USA. samir.narayan@ucdmc.ucdavis.edu

Nature Clinical Practice. Oncology
|September 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Sequencing Paradox of Immunotherapy and Thoracic Radiotherapy.

JAMA oncology·2026
Same author

The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202.

Advances in radiation oncology·2026
Same author

Automatic Tenure-Clock Extensions as a Safeguard Against Defunding.

Annals of internal medicine·2026
Same author

Performance of Stereotactic Radiotherapy vs Hippocampal-Avoidance Whole Brain Radiation.

JAMA oncology·2026
Same author

Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study.

Clinical colorectal cancer·2026
Same author

Jurisdiction firearm prevalence and increasing suicide in United States adolescents and young adults.

Journal of the National Medical Association·2025

Combined therapies improve Pancoast tumor treatment. Neoadjuvant chemoradiation shows promise for superior sulcus tumors, even with positive N2 lymph nodes, enhancing surgical outcomes and patient prognosis.

Area of Science:

  • Thoracic Oncology
  • Surgical Oncology
  • Radiation Oncology

Background:

  • Pancoast tumor management presents long-standing challenges for oncologists.
  • Positive N2 lymph nodes significantly impact prognosis and treatment decisions for superior sulcus tumors.
  • Historically, patients with N2 disease were often excluded from neoadjuvant chemoradiation trials.

Purpose of the Study:

  • To review the evolving treatment strategies for Pancoast tumors.
  • To highlight the importance of combined treatment modalities.
  • To discuss ongoing clinical trials and future research directions.

Main Methods:

  • Review of retrospective studies and clinical trial data.
  • Evaluation of the role of positron emission tomography (PET) in staging and response assessment.

Related Experiment Videos

  • Analysis of outcomes with combined modality treatments including chemotherapy, radiation, and surgery.

    • Main Results:

    • Combined treatment modalities have improved Pancoast tumor management outcomes.
    • Neoadjuvant chemoradiation has demonstrated significant improvements in complete resection rates.
    • Positive N2 lymph nodes are increasingly considered in treatment paradigms.

    Conclusions:

    • Combined neoadjuvant chemotherapy and radiation therapy enhance surgical resection rates for Pancoast tumors.
    • Further investigation into surgery for N2-positive disease and advanced imaging for response assessment is warranted.
    • Ongoing trials are exploring taxane-based chemotherapy and prophylactic cranial irradiation.